<< Back to Investments

KannaLife Sciences

KannaLife Sciences, Inc. (“KannaLife”), is a bio-pharmaceutical and phyto-medical company involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants. KannaLife Sciences currently holds an exclusive license with National Institutes of Health – Office of Technology Transfer (“NIH-OTT”) for the Commercialization of U.S. Patent #6630507, “Cannabinoids as Antioxidants and Neuroprotectants” (the “‘507 Patent”). KannaLife is currently conducting research and development at the Bucks County Pennsylvania Biotechnology Center in Doylestown, PA, for a target drug candidate to treat Hepatic Encephalopathy (“HE”) and Chronic Traumatic Encephalopathy (“CTE”). HE and CTE are both oxidative stress related diseases that affects the cognitive and behavioral functions, and the wellness of the brain.  


4 Knoll Court
Lloyd Harbor, New York 11743
United States of America
(516) 669-3219

July 9, 2012

KannaLife Sciences, Inc. Signs Exclusive License Agreement with National Institutes of Health Office of Technology Transfer (NIH-OTT) to commercialize new cannabinoid-based treatment for Hepatic Encephalopathy.

March 7, 2013

KannaLife Sciences Announces $1.5M Series A Financing From Medical Marijuana Inc. (OTC:MJNA) And CannaVest Corp. (OTC:FCLS)

April 4, 2013

KannaLife Sciences, Inc. Signs Research and Development Agreements With Advanced Neural Dynamics and IteraMed in the Discovery of Novel Neuroprotectants

August 13, 2013

KannaLife Sciences, Inc. Announces Creation of South Park Pharmaceuticals

December 20, 2013

KannaLife Sciences, Inc. Signs Materials Transfer and Testing Agreement with Baruch S. Blumberg Institute

March 31, 2014

KannaLife Sciences, Inc. and Kannaway, LLC Sign Long Term Sales, Marketing and Product Development Agreement

August 4, 2014

KannaLife Sciences, Inc. Signs New License Agreement with National Institutes of Health (NIH) for Treatment of Chronic Traumatic Encephalopathy

September 29, 2017


FORMER KANSAS CITY CHIEFS PLACEKICKER SPOKE WITH FOX BUSINESS, CBS SPORTS, NBC AND I24 NEWS. SAN DIEGO, Sept. 29, 2017 — Medical Marijuana, Inc. (OTC:MJNA), the first publicly traded cannabis company in the United States, today announced that portfolio company KannaLife Sciences‘ new

August 4, 2017

Medical Marijuana, Inc. Subsidiary Kannaway® Recognizes Second Brand Ambassador in Company History to Achieve International Director Title

SAN DIEGO, Aug. 4, 2017 — Medical Marijuana, Inc. (OTC: MJNA) announced today that its subsidiary Kannaway, LLC, the first hemp lifestyle network to offer cannabidiol (CBD) hemp botanical products, is recognizing Randy Schroeder as its second Brand Ambassador in Company history to reach the rank of

July 6, 2017

Kannalife Sciences Participates in 27th Annual International Cannabinoid Research Society (ICRS) Symposium

Company Presents Science Behind Mechanism of Action of CBD and its Own Patented CBD-derived Molecule KLS-13019 NEW YORK, July 5, 2017 /PRNewswire/ — Kannalife Sciences, Inc. (“Kannalife”), a bio-pharmaceutical and phyto-medical company, announced today that it presented its findings at the 27th Annual ICRS Symposium on

March 1, 2017

Medical Marijuana, Inc. Clarifies Operations Unaffected by White House Statements Hinting at Recreational Marijuana Crackdown

SAN DIEGO, March 1, 2017 — Medical Marijuana, Inc. (OTC:MJNA), the first publicly traded cannabis company in the United States, is reassuring customers, shareholders, and the public that the company’s operations in the federally legal hemp cannabidiol (CBD) market are unaffected by

June 9, 2016

Medical Marijuana, Inc. CEO to Speak on Nutritional and Therapuetic Benefits of Hemp at 3rd Annual Cannabis World Congress and Business Expo

RSHO Advocate Penny Howard to Share Story on How Her Fight to Save Daughter Harper Helped Legalize New Markets and Change Lives in Latin America SAN DIEGO, CA – June 9, 2016 – Medical Marijuana, Inc. (OTC: MJNA) today announced that at

December 22, 2015

Medical Marijuana, Inc. and Kannalife Sciences, Inc. Announce Joint Effort to Raise Awareness for CTE Research

www.treatCTE.org Opens Opportunity for Research and Development of Grassroots Fundraiser “Show Your Green” PSA Drives Awareness Campaign with Former NFL Star Marvin Washington NEW YORK – December 22, 2015 – Medical Marijuana, Inc. (OTC Pink: MJNA) is proud to announce

December 18, 2015

Medical Marijuana, Inc.’s Portfolio Company KannaLife’s Spokesman, Ex-NFL Star Marvin Washington to Appear on ESPN’s Outside the Lines

Former Super Bowl Champ to Appear on ESPN Panel Focused on Will Smith’s New Film Concussion, Discussing Traumatic Brain Injuries and Web Site www.TreatCTE.org NEW YORK, Dec. 18, 2015 (GLOBE NEWSWIRE) – Medical Marijuana, Inc. (OTC Pink:MJNA) is proud to

November 5, 2015

Fox News: Will Pot Save NFL?

KannaLife was featured on Sports Court as Tamara Holder and Marvin Washington discussed the new push to swap pain pills with pot to treat NFL injuries. “He’s seen guys leave the game addicted to pharmaceuticals and so have I, but

October 8, 2015

The Man Guide: The Case For Cannabidoil

KannaLife Sciences was featured in an article by the MAN guide about how the same government that’s waging war against marijuana also has a patent on its health benefits. The team had examined cannabinoids—chemicals unique to the cannabis plant—and found that

September 22, 2015

Bumbbells and Dragons: League of Concussions: The NFL and Head Injuries

KannaLife Sciences was featured in an article by Bumbbells and Dragons about a new development in treating brain injuries. “We were lucky enough to sit down with former NFL defensive end and Super Bowl XXXIII champion, Marvin Washington to talk

August 19, 2015

Medical Marijuana, Inc’s Portfolio Investment Company Kannalife Sciences Announces Publication of Its Global PCT Patent Covering Cannabidiol-like Neuroprotective Agents

Milestone Accomplishment to Lead KSI to Further Patents and IP SAN DIEGO, Aug. 14, 2015 (GLOBE NEWSWIRE) — Medical Marijuana, Inc. portfolio investment company Kannalife Sciences, Inc. has announced the publication of its global WIPO/PCT Patent WO2015/106108A2 – ‘Novel Functionalized

June 12, 2015

HempMeds® Participates In New York Cannabis World Congress & Business Expo

“Low THC Cannabis” Retail Products Showcased in New York by Hemp Industry Innovator San Diego, CA – June 3, 2015 – The entrepreneurial spirit is thriving in New York. As the state prepares for medical cannabis availability, cultivation and dispensary

April 30, 2015

KannaLife™ Sciences, holder of 2 licenses from the United States National Institutes of Health, Featured in Sanjay Gupta CNN Documentary

From Historic Federal Government Collaboration and Hard-Hitting Topics Including CTE and HE, KannaLife Sciences Shares Cannabis Industry Advances SAN DIEGO, April 20, 2015 (GLOBE NEWSWIRE) — KannaLife Sciences (“KannaLife”), a Medical Marijuana, Inc. (OTC PINK:MJNA) portfolio company, is on the

March 4, 2015

Kannalife Sciences, Inc. Adds Dr. Bennet Omalu to its Scientific Advisory Board

Huntington, NY – Kannalife Sciences, Inc. (“Kannalife”) announces that Dr. Bennet Omalu, MD has joined its Scientific Advisory Board to assist the Company in the advancement of its research and development efforts towards the use of cannabinoid therapeutics for the

January 26, 2015

Huffington Post: The NFL Needs to Rethink Marijuana

Kannalife Sciences was featured in an article by Huffington Post NFL’s current drug policy and how Marijuana could be used as a legitimate option to help players medical condition. “The NFL is the preeminent sports league in the U.S. but

January 6, 2015

Captial New York: Lobbyists prepare for medical marijuana boomlet

KannaLife Sciences was mentioned in an article by Capital New York written by Laura Nahmias about the recent surge for in business from the legalization of medical marijuana, and their plan for acquiring state licenses. “Manufacturers most likely to succeed

December 7, 2014

Video: Introduction to Kannalife Sciences

An introduction to Kannalife Sciences.

December 2, 2014

National News Coverage for KannaLife Sciences, Inc. an MJNA Portfolio Company

FDA Approved Cannabis-Based Drug Development Fuels Discussions Regarding NFL Players, Concussions, and CTE   SAN DIEGO, Dec. 2, 2014 (GLOBE NEWSWIRE) — News of a potential NFL lawsuit settlement and KannaLife Sciences, Inc. (“KannaLife”) license from National Institutes of Health

November 20, 2014

Video: HLN Interview by Hanna Gordola with Thoma Kikis and Marvin Washington

Interview by Hanna Gordola with Thoma Kikis and Marvin Washington about Kannalife Sciences and their research on how “pot” may help treat concussions. And discussion about former players suing the NFL for concussion they’re suffered in the league.

Kannalife Sciences currently focuses on researching applications of cannabinoids in the following areas: